Pocenbrodib hydrochloride is under clinical development by Pathos AI and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase I drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pocenbrodib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pocenbrodib hydrochloride overview
Pocenbrodib hydrochloride (P-300) is under development for the treatment of metastatic castration-resistant prostate cancer. The drug candidate acts by targeting CREB (cAMP-responsive element-binding protein) binding protein (CBP)/E1A Binding Protein P300 (EP300). It is administered through oral route.
Pathos AI overview
Pathos AI is a clinical stage biotechnology company that develops drugs to address unmet need in multiple cancer diseases. The company uses an artificial intelligence (AI) and machine learning (ML) based platforms for drug development. Its drug pipeline portfolio includes Pocenbrodib for the treatment of advanced prostate cancer, and P-500 (previously PRT811) for the treatment of solid tumors, including high-grade glioma and uveal melanoma. Pathos AI developing drugs to treat prostate cancer, breast cancer, brain tumors, solid tumors, and other rare diseases. Pathos AI is headquartered in Chicago, Illinois, the US.
For a complete picture of Pocenbrodib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
